Login to Your Account

Synageva posts positive top-line data for enzyme replacement therapy

By Michael Fitzhugh
Staff Writer

Tuesday, July 1, 2014

Rare disease specialist Synageva Biopharma Corp. reported top-line phase III data showing that sebelipase alfa, its enzyme replacement therapy for LAL deficiency, met its primary endpoint and several secondary endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription